Andrea Ashford-Hicks is the Chief Executive Officer of Cayuga Biotech. She has more than 20 years of biopharmaceutical industry experience spanning development, commercial and strategy. Prior to Cayuga, Ms. Ashford-Hicks served as Senior Vice President of Late-Stage Development and Commercialization at Enzyvant Therapeutics. Under her leadership, Enzyvant received FDA approval for RETHYMIC® for pediatric congenital athymia. She also has contributed to multiple regulatory approvals and product launches over her career in leadership roles at Agenus, EMD Serono, Janssen, Allos, and Pfizer. Ms. Ashford-Hicks earned a dual degree in Biology from the University of Pennsylvania’s Wharton school and College of Arts and Sciences.
